Chimicles & Tikellis is investigating a potential class action lawsuit on behalf of Medicare patients that have received a BRCA 1 genetic test from Myriad Genetics. There have been reports that Myriad is categorizing the test as “screening” instead of “diagnostic”, resulting in Medicare denying coverage and patients paying for the test out of pocket. Patients with the BRCA 1 gene have a predisposition to developing breast cancer. The BRCA 1 genetic test is an influential test in determining a patient’s treatment. Myriad Genetics is the sole processor of BRCA 1 genetic tests. C&T is investigating reports that Myriad Genetics has improperly denied Medicare coverage, requiring patients to pay out of pocket and is seeking to recover on behalf of those patients.
If you have received a BRCA 1 genetic test from Myriad Genetics and paid out of pocket please use the “Email us about this Case” button to contact the attorneys for this case.
[accordion-item id=”item-1″ title=”Email us about this Case”]
[accordion-item id=”item-2″ title=”Alert me to Case updates”]
[widgets_on_pages id=”Email Alerts”]